The molecular basis of limited-stage DLBCL

2022 Fiscal Year Final Research Report

• Project/Area Number: 21K16262
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 54010:Hematology and medical oncology-related
• Research Institution: University of Tsukuba
• Principal Investigator: Suehara Yasuhito 筑波大学, 附属病院, 病院講師 (90844811)
• Project Period (FY): 2021-04-01 – 2023-03-31
• Keywords: 悪性リンパ腫 / オミクス研究

Outline of Final Research Achievements

The stage is a well-established prognostic factor in diffuse large B-cell lymphoma (DLBCL). The molecular basis harboring limited-stage or advanced disease has not been adequately explored when considering stage as a phenotype. We aimed to identify limited-stage signatures (LSs) characteristic of limited-stage DLBCL, investigate the relationship between the presence or absence of LSs and prognosis, and their correspondence with known DLBCL genetic/transcriptomic subtypes. We re-analyzed 1000 whole exome sequencing (WES) and 775 RNA sequencing (RNA-seq) datasets from EGAS00001002606.

Free Research Field

悪性リンパ腫

Academic Significance and Societal Importance of the Research Achievements

限局期DLBCLは全体の約30%を占め、PET-CTによる評価や一部の若年者では生存率を損なうことなく治療強度を減弱できるエビデンスが出てきている。一方で、5-10%程度は初回治療で奏効が得られない、あるいは再発をする。まだ成果が得られていないが、limited-stage signatureが限局期DLBCLの中での層別化に寄与できれば、より適切な治療戦略に繋がると考えられる。